Kyverna Therapeutics Initiated at Neutral by HC Wainwright & Co.

Kyverna Therapeutics Initiated at Neutral by HC Wainwright & Co.

Dow Jones06:30 ET

Kyverna Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/03/2024 -2.91% HC Wainwright & Co. → $8 Initiates Coverage On → Neutral 03/04/2024 373.3% JP Morgan → $

Benzinga06:18 ET

Express News | Kyverna Therapeutics, Inc : H.c. Wainwright Initiates Coverage With Neutral Rating and Target Price $8

Reuters06:06 ET

Sector Update: Health Care Stocks Higher Late Afternoon

Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index up 0.2% and the Health Care Select Sector SPDR Fund (XLV) adding 0.3%. The iShares Biotechnology ETF (IBB) rose

MT NewswiresJun 20 16:02 ET

Kyverna Gains as FDA Clears Trial for Lead Therapy

Seeking AlphaJun 20 13:55 ET

Kyverna Therapeutics Gets FDA IND Clearance for KYV-101

By Chris Wack Kyverna Therapeutics said it has received clearance for its Investigational New Drug, or IND, application by the U.S. Food and Drug Administration for its T-cell product candidate, KYV-

WSJJun 20 09:30 ET